Naslov
Biochemical markers of bone turnover in hemodialysis patients treated with paricalcitol

Autori
Pavlović, Draško ; Vrkić, Nada ; Tešija Kuna, Andrea ; Pavlović, Nikola ; Mirošević, Gorana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the 28th Annual Conference on Peritoneal Dialysis, 14th International Symposium on Hemodialysis, and 19th Annual Symposium on Pediatric Dialysis ; u: Hemodialysis International 12 (2008) (1) / Nissenson, Allen R. - Columbia (MO) : Wiley-Blackwell, 2008, 143-144

Skup
Annual Conference on Peritoneal Dialysis (28 ; 2008) ; International Symposium on Hemodialysis (14 ; 2008) ; Annual Symposium on Pediatric Dialysis (19 ; 2008)

Mjesto i datum
Orlando (FL), Sjedinjene Američke Države, 02.03.2008. - 04.03.2008

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
paracalcitol; hemidialysis; bone markers

Sažetak
Vitamin D therapy is important in the management of secondary hyperparathyroidism (SHPT). The effects of calcitriol and its an-alogs on PTH secretion and parathyroid gland hyperplasia have been well established. Several studies have also demonstrated the effect on bone metabolism. Besides its selective effect on vitamin D receptor, it seems that paricalcitol has a different effect on bone cells The aim of the study was to assess the short-term effect of paricalcitol on bone metabolism in hemodialysis patients with secondary hyperparathyroidism by using biochemical markers of bone formation and resorption. Seven hemodialysis patients (PTH > 300 pg/ml) were treated with paricalcitol. The dose of par-icalcitol was 5 meg 3 times per week. At the start of therapy and 3 months later serum total procollagen 1 N-propeptide (P1NP) and osteocalcin (OC) as bone formation markers, and beta-cross laps (Beta-CTX) as a bone resorption marker, were determined by the electrochemoluminescence immunoassay. PTH was deter-mined by radioimmunometric assay. All patients underwent hemodialysis treatment for 4 hours 3 times per week. Dialysate calcium concentration was 1.5mmol/L ; sevelamer hydrochloride was used as a phosphate binder. After 3 months of treatment, a significant reduction, of PTH (average 68%) was observed. At the same time, the average reduction of OC was 26%, P1NP 41%, and Beta-CTX 51%. The results indicate the reduction of bone turn-over, i.e. bone formation, and a bit more bone resorption. The reduction of Beta-CTX was the closest to the reduction of PTH. We need to confirm these results on larger group of patients and for a longer follow up period.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti, Farmacija

POVEZANOST RADA